ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2301

T Cell Proliferative Response To Type II Collagen In Patients With Rheumatoid Arthritis

Nida Saleem1, Tahir Aziz Ahmed2, Javaid Mahmood Malik3, Mushtaq Ahmed4 and Mukarram Bashir5, 1IMMUNOLOGY, Armed Forces Institute Of Pathology, RAWALPINDI, Pakistan, 2Dept of Immunology, Armed Forces Institute of Pathology, Rawalpindi, Pakistan, 3Rahmat Noor Clinic and Arthritis Research Centre, Rawalpindi, Pakistan, 4Medicine, Military Hospital Rawalpindi, rawalpindi, Pakistan, 5IMMUNOLOGY, Armed Forces Institute Of Pathology, rawalpindi, Pakistan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: CD T cells, collagen and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis-Clinical Aspects III: Outcome Measures, Socioeconomy, Screening, Biomarkers in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

To compare the frequency of Collagen II reactive T cells in RA patients and healthy control and evaluating the relationship of Collagen II reactive T cells with disease activity in RA patients.

Materials and Methods:

Patients with a clinical diagnosis of Rheumatoid arthritis on fulfilling 1987 ACR criteria were included in the study. Patients were compared with a group of age and gender matched healthy subjects. T cell proliferative response was assessed against Bovine Collagen II, PHA (positive control) and RPMI (negative control) by measuring incorporation of the 5-bromo-2- deoxyuridine (BrdU) into DNA of proliferating cells and expression of CD25 on proliferating cells and was subsequently detected with monoclonal antibodies (BrdU-moAb and CD25-moAb)  as percentage of CD3+/BrdU+ and CD3+/CD25+ T-cells, respectively.

RA patients were classified into three groups of mild, moderate and severe disease activity as per Simplified disease activity index for RA. Four parameters, frequency of CD3+/BrdU+ , frequency of CD3+/CD25+ T-cells, Mean Fluorescent Intensity (MFI) of BrdU-FITC and MFI of CD25-FITC were compared in mild, moderate and severe disease activity groups.

Results:

Five male and twenty five female RA patients with an age range of 28-60 years (mean 42 years) and 25-58 years (mean 36 years) respectively were studied. Percentages of CD3+/CD25+ cells and CD3+/BrdU+ cells in T lymphocytes from RA patients induced by Collagen II were much higher (45.22% and 53.45%) than those observed for T lymphocytes in control group (33.51% and 45.22% ). The difference was statistically significant (p<0.05).

Statistically significant differences were observed when frequency of CD3+/BrdU+ cells and CD3+/CD25+ cells along with MFI of BrdU-FITC and CD25-FITC was compared between the three disease activity groups, mild, moderate and severe in patients (p<0.05).

Conclusion:

These observations suggest that Collagen II is an important auto antigen in joints of RA patients with Collagen II reactive T cells playing a critical role in pathogenesis of RA and Collagen II reactive T lymphocytes may be used as a specific prognostic laboratory marker for assessment of disease activity in RA.

 


Disclosure:

N. Saleem,
None;

T. A. Ahmed,
None;

J. M. Malik,
None;

M. Ahmed,
None;

M. Bashir,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/t-cell-proliferative-response-to-type-ii-collagen-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology